CA224-056: Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer (clinicaltrials.gov) - Sep 10, 2026 - P2 | N=80 | Active, not recruiting | Sponsor: Dan Zandberg | Trial completion date: Oct 2027 ➔ Apr 2028 | Trial primary completion date: Oct 2027 ➔ Apr 2026
Trial completion date • Trial primary completion date • Head and Neck Cancer • Oncology • Oropharyngeal Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Carcinoma of Head and Neck • LAG3
|